Next Article in Journal
Dendritic Cell-Derived Exosomes in Cancer Immunotherapy
Next Article in Special Issue
Y-Site Compatibility Studies of Parenteral Nutrition and Other Intravenous Medications in Neonatal and Pediatric Patients: A Review of the Literature Evidence
Previous Article in Journal
Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy
Previous Article in Special Issue
Y-Site Compatibility Studies of Ketoprofen with Parenteral Nutrition Admixtures for Central and Peripheral Administration
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 8
10.3390/pharmaceutics15082069
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility

by
Anthony Martin Mena
1,*,
Laura Négrier
1,
Anthony Treizebré
2,
Marie Guilbert
2,
Lucille Bonnaire
1,
Valentine Daniau
1,
Gabie Leba Bonki
1,
Pascal Odou
1,
Stéphanie Genay
1 and
Bertrand Décaudin
1
1
Univ. Lille, CHU Lille, ULR 7365—GRITA—Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France
2
Univ. Lille, CNRS, Centrale Lille, Univ. Polytechnique Hauts-de-France, UMR 8520—IEMN—Institut d’Electronique de Microélectronique et de Nanotechnologie, F-59000 Lille, France
*
Author to whom correspondence should be addressed.
Pharmaceutics 2023, 15(8), 2069; https://doi.org/10.3390/pharmaceutics15082069
Submission received: 30 June 2023 / Revised: 25 July 2023 / Accepted: 28 July 2023 / Published: 1 August 2023
(This article belongs to the Special Issue Advances in Parenteral Formulations)
Browse Figures
Versions Notes

Abstract

Background: Drug incompatibility is defined as a physical-chemical reaction between two or more injectable drugs and that results mainly in precipitation or insolubility. Several strategies for reducing incompatibilities have been implemented empirically in intensive care units. However, these strategies have never been compared directly (and particularly in terms of the particulate load and drug mass flow rate) under standardized conditions. The objective of the present in vitro study was to evaluate the impact of various strategies for preventing incompatibility between simultaneously infused vancomycin and piperacillin/tazobactam. Methods: An in-line filter, a dilute vancomycin solution (5 mg/mL), and an alternative saline administration line were evaluated separately. The infusion line outlet was connected to a dynamic particle counter. The antibiotic concentration was measured in an HPLC-UV assay. Result: The use of an in-line filter and an alternative saline administration route did not significantly reduce the particulate load caused by vancomycin-piperacillin/tazobactam incompatibility. Dilution of the vancomycin solution was associated with a significantly lower particulate load and maintenance of the vancomycin mass flow rate. Discussion: It is important to systematically compare the efficacy of strategies for preventing drug incompatibility. The use of diluted vancomycin solution gave the best results in the case of vancomycin-piperacillin/tazobactam incompatibility.
Keywords: vancomycin; piperacillin/tazobactam; drug incompatibility; infusion; particulate load; in-line filter vancomycin; piperacillin/tazobactam; drug incompatibility; infusion; particulate load; in-line filter

Share and Cite

MDPI and ACS Style

Martin Mena, A.; Négrier, L.; Treizebré, A.; Guilbert, M.; Bonnaire, L.; Daniau, V.; Leba Bonki, G.; Odou, P.; Genay, S.; Décaudin, B. Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility. Pharmaceutics 2023, 15, 2069. https://doi.org/10.3390/pharmaceutics15082069

AMA Style

Martin Mena A, Négrier L, Treizebré A, Guilbert M, Bonnaire L, Daniau V, Leba Bonki G, Odou P, Genay S, Décaudin B. Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility. Pharmaceutics. 2023; 15(8):2069. https://doi.org/10.3390/pharmaceutics15082069

Chicago/Turabian Style

Martin Mena, Anthony, Laura Négrier, Anthony Treizebré, Marie Guilbert, Lucille Bonnaire, Valentine Daniau, Gabie Leba Bonki, Pascal Odou, Stéphanie Genay, and Bertrand Décaudin. 2023. "Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility" Pharmaceutics 15, no. 8: 2069. https://doi.org/10.3390/pharmaceutics15082069

APA Style

Martin Mena, A., Négrier, L., Treizebré, A., Guilbert, M., Bonnaire, L., Daniau, V., Leba Bonki, G., Odou, P., Genay, S., & Décaudin, B. (2023). Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility. Pharmaceutics, 15(8), 2069. https://doi.org/10.3390/pharmaceutics15082069

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop